MeSH tree: C15.604
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive ...
Feb 9, 2026
0
8
Our lymphatic system is like a big network of roots spread throughout the body. It serves as part of our immune system, transporting immune cells and filtering excess fluid (lymph) before returning it to the bloodstream. ...
Feb 9, 2026
0
9
In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received ...
Feb 9, 2026
0
6
A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved for treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, ...
Feb 5, 2026
0
9
With months left of flu season, influenza cases are on the rise in California and transmission is high in the San Francisco Bay Area, data shows.
Feb 2, 2026
0
9
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have identified a mechanism that protects the female brain from genetic diseases. Although one of the two X chromosomes is switched off in female cells ...
Feb 2, 2026
0
22
Infectious mononucleosis, often called "mono," is a viral illness best known for causing extreme fatigue, sore throat and swollen glands.
Feb 2, 2026
0
6
Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according ...
Jan 25, 2026
0
13
Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, ...
Jan 7, 2026
0
15
Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia virus type I (HTLV-1) drives the development of adult T-cell leukemia-lymphoma (ATL), one of the most ...
Jan 5, 2026
0
14
